Health
Osimertinib offers a hint of added benefit for NSCLC patients who have received adjuvant chemotherapy – News-Medical.net
Osimertinib was the first drug to be approved for adjuvant treatment after complete tumour resection in adults with stage IB…
Osimertinib was the first drug to be approved for adjuvant treatment after complete tumour resection in adults with stage IB to IIIA non-small cell lung cancer (NSCLC). In an early benefit assessment, the German Institute for Quality and Efficiency in Health…
Continue Reading
-
General21 hours agoInternal Revenue Service starts cutting 20,000 workers
-
Noosa News20 hours agoMan killed, woman seriously injured in collision in Wongabel, Atherton Tablelands, Queensland
-
Noosa News20 hours agoMoreton Bay oyster farm survives cyclone with help of wave wall innovation
-
Business22 hours ago$10,000 invested in ANZ shares 5 years ago is now worth…